Phone Number: 97********
Who is IBIO
At iBio, we are using our Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat ca...
Read More
-
Headquarters: 8800 Hsc Pkwy, Bryan, Texas, 77807, United States
-
Date Founded: 2008
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Robert Kay
Email
Phone
Industry: Biotechnology
SIC Code: 2833
|
NAICS Code: 325411 |
Show More
iBio Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding IBio
Answer: iBio's headquarters are located at 8800 Hsc Pkwy, Bryan, Texas, 77807, United States
Answer: iBio's phone number is 97********
Answer: iBio's official website is https://ibioinc.com
Answer: iBio's revenue is $5 Million to $10 Million
Answer: iBio's SIC: 2833
Answer: iBio's NAICS: 325411
Answer: iBio has 11-50 employees
Answer: iBio is in Biotechnology
Answer: iBio contact info: Phone number: 97******** Website: https://ibioinc.com
Answer: At iBio, we are using our Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is not left to chance but guided by artificial intelligence to make therapeutic development smarter, more precise, and ultimately faster. With our Discovery Platform, we are pursuing hard-to-drug targets with greater potential and less competition. We have nine immuno-oncology candidates in our pipeline, including those for the potential treatment of solid tumors, glioblastoma, and head and neck cancers. An essential challenge to developing antibody drugs is that traditional discovery technologies employ a high degree of randomness. Creating an antibody with a set of desired qualities requires repeated attempts until the optimal result is achieved, often by chance. While this approach has yielded valuable therapeutics in the past, that outcome is rare, with fewer than 1 in 1,000 targets ever reaching the clinic. Traditional antibody development methods are time-consuming and costly, and we believe ultimately produce fewer potentially life-saving drugs than possible. We believe that our Discovery Platform offers the precision required to solve this problem while also identifying the most challenging targets.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month